{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:57:18Z","timestamp":1780469838361,"version":"3.54.1"},"reference-count":33,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T00:00:00Z","timestamp":1494288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lunds Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Prognostic factors in patients with localized primary cutaneous malignant melanoma (<jats:styled-content style=\"fixed-case\">CMM<\/jats:styled-content>) are well described. However, prognostic factors for recurrence are less documented.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of this study was to identify prognostic risk factors for first recurrence in patients with localized stages I\u2010<jats:styled-content style=\"fixed-case\">II CMM<\/jats:styled-content> using population\u2010based data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study included 1437 <jats:styled-content style=\"fixed-case\">CMM<\/jats:styled-content> patients registered in one region of Sweden during 1999\u20132012 follow\u2010up through 31 December 2012. To identify first recurrence of <jats:styled-content style=\"fixed-case\">CMM<\/jats:styled-content> disease, data from a care data warehouse, the pathology and radiology department registries were used. Patients were also followed through a census register and the national Cause of Death Register.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The 5\u2010 and 10\u2010year recurrence\u2010free survival (RFS) were 85.7% and 81.2%, respectively. The most common site of first recurrence was regional lymph node metastasis closely followed by distant metastasis. After adjusting for all prognostic factors, women had 50% lower risk of recurrence than men (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content> = 0.5, 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 0.4\u20130.7) and patients \u226570 had higher risk compared to patients 55\u201369 years (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content> = 1.7, 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 1.2\u20132.5). Other significant prognostic factors for risk of recurrence were tumour thickness, presence of ulceration, Clark's level of invasion and histogenetic type.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Tumour thickness was found to be the predominant risk factor for recurrence. The prognostic factors for recurrence coincided with prognostic factors for <jats:styled-content style=\"fixed-case\">CMM<\/jats:styled-content> death. The most common site of first recurrence in stages I\u2010<jats:styled-content style=\"fixed-case\">II CMM<\/jats:styled-content> is regional lymph node (42.8%) closely followed by distant metastases (37.6%), a fact which has to be taken into consideration when choosing follow\u2010up strategies.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.14280","type":"journal-article","created":{"date-parts":[[2017,4,17]],"date-time":"2017-04-17T18:22:45Z","timestamp":1492453365000},"page":"1468-1474","source":"Crossref","is-referenced-by-count":32,"title":["Prognostic risk factors of first recurrence in patients with primary stages I\u2013II cutaneous malignant melanoma \u2013 from the population\u2010based Swedish melanoma register"],"prefix":"10.1111","volume":"31","author":[{"given":"J.","family":"Lyth","sequence":"first","affiliation":[{"name":"Local Health Care Research and Development Unit County of \u00d6sterg\u00f6tland Link\u00f6ping Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Falk","sequence":"additional","affiliation":[{"name":"Department of Medical and Health Sciences Division of Community Medicine Primary Care Link\u00f6ping University Link\u00f6ping Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Maroti","sequence":"additional","affiliation":[{"name":"Department of Oncology County Hospital Ryhov J\u00f6nk\u00f6ping Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Department of Oncology and Pathology Karolinska Institutet Stockholm Sweden"},{"name":"Department of Oncology Karolinska University Hospital Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ingvar","sequence":"additional","affiliation":[{"name":"Department of Surgery Sk\u00e5ne University Hospital, Clinical Sciences Lund University Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,9]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27616"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70546-1"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.4799"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.1627"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5212-5"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.029"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13171"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12095"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20602"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30407"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2004.30376.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.12.015"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-009-9350-y"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.16.3635"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0584"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.5031"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.4408"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13483"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30023"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032955"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-007-9347-2"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04867.x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/028418699431122"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9098(199804)67:4<228::AID-JSO4>3.0.CO;2-A"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830801)52:3<575::AID-CNCR2820520333>3.0.CO;2-6"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.05.005"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.04.031"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09883.x"},{"key":"e_1_2_6_30_1","unstructured":"New Zealand Guideline group.Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand.2008.http:\/\/www.cancer.org.au\/content\/pdf\/HealthProfessionals\/ClinicalGuidelines\/ClinicalPracticeGuidelines-ManagementofMelanoma.pdf(last accessed: 03 May 2017)."},{"key":"e_1_2_6_31_1","unstructured":"Nationellt v\u00e5rdprogram malignt melanom.2014.http:\/\/www.cancercentrum.se\/samverkan\/cancerdiagnoser\/hud-och-ogon\/vardprogram\/(last accessed: 03 May 2017)"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611299"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60898-4"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.14280","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T23:51:44Z","timestamp":1695513104000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.14280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1111\/jdv.14280"],"URL":"https:\/\/doi.org\/10.1111\/jdv.14280","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,9]]}}}